SCHEMBL30967840

SCHEMBL30967840

Cc1c(Oc2cccc(C#N)c2)ccc2[nH]ccc12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PRKCQ Q04759 3/20 0.47
▸ PRKCD Q05655 3/20 0.47
▸ BRD4 O60885 2/20 0.46
▸ AR P10275 2/20 0.46
▸ EPAS1 Q99814 5/20 0.46
▸ RHEB Q15382 2/20 0.45
▸ EGFR P00533 1/20 0.41
▸ ERBB2 P04626 1/20 0.41
▸ ERBB3 P21860 1/20 0.41
▸ ERBB4 Q15303 1/20 0.41
▸ VEGFA P15692 1/20 0.41
▸ IMPDH2 P12268 1/20 0.40
▸ IMPDH1 P20839 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.40
▸ CYP19A1 P11511 1/20 0.39
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27275421 1.00 PRKCQ (0.47) PRKCQPRKCDBRD4AREPAS1
SCHEMBL27275422 0.85 EPAS1 (0.49) BRD4AREPAS1RHEBEGFR
SCHEMBL29337971 0.84 BRD4 (0.46) BRD4AREPAS1RHEBEGFR
SCHEMBL29237661 0.82 EPAS1 (0.49) BRD4AREPAS1RHEBEGFR
SCHEMBL30967802 0.82 EPAS1 (0.49) BRD4AREPAS1RHEBEGFR
SCHEMBL29336676 0.82 BRD4 (0.45) BRD4AREPAS1RHEBEGFR
SCHEMBL30967931 0.81 BRD4 (0.46) BRD4AREPAS1RHEBEGFR
SCHEMBL30967796 0.81 BRD4 (0.44) BRD4AREPAS1RHEBEGFR
SCHEMBL29237564 0.81 BRD4 (0.44) BRD4AREPAS1RHEBEGFR
SCHEMBL29237251 0.81 BRD4 (0.46) BRD4AREPAS1RHEBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624051-B2 Macrocyclic compounds, compositions, and methods of using thereof GENZYME CORPORATION (US) 2026-05-12 — — US disclosed
US-20260008786-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SCHRODINGER, LLC 2026-01-08 — — US disclosed
US-20260008785-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SCHRODINGER, LLC 2026-01-08 — — US disclosed
US-20250197422-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SCHRODINGER, LLC 2025-06-19 — — US disclosed
US-20240279220-A1 INDOLE COMPOUNDS AND METHODS OF USE SIONNA THERAPEUTICS INC. 2024-08-22 — — US disclosed
CN-118201919-A Indole compounds and methods of use 健赞公司 2024-06-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279220-A1 INDOLE COMPOUNDS AND METHODS OF USE CFTR, INMT, IDO1 PRKCQ 2010/4885PRKCD 2233/4885BRD4 651/4885
US-12624051-B2 Macrocyclic compounds, compositions, and methods of using thereof CFTR, ABCC3, ABCD3 PRKCQ 450/4885PRKCD 201/4885BRD4 2704/4885
US-20260008786-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCC3, ABCD3 PRKCQ 450/4885PRKCD 201/4885BRD4 2704/4885
US-20260008785-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCC3, ABCD3 PRKCQ 449/4885PRKCD 195/4885BRD4 2758/4885
US-20250197422-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCB1, PKD1 PRKCQ 447/4885PRKCD 581/4885BRD4 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback